Alentis Therapeutics is developing breakthrough treatments for fibrotic and rare diseases and associated cancers. The company’s lead candidates are monoclonal antibodies that are highly selective for exposed and non-junctional Claudin-1 (CLDN1). Non-junctional CLDN1 is a previously unexploited target with a unique mechanism of action that plays a key role in the pathology of liver, kidney, lung fibrosis, and solid tumors.

Unlike current therapies in fibrosis, which mostly address the disease indirectly, Alentis’ pioneering approach has the potential to directly modify and reverse the course of disease progression.

Upon injury, CLDN1 is upregulated and found outside of the tight junction. Alentis’ pioneering approach utilizes the high specificity and potency of our unique anti-CLDN1 monoclonal antibodies that target non-junctional CLDN1 and revert the course of fibrotic diseases and associated cancers. This approach exploits a unique and differentiated mechanism of action, allowing treatment of both fibrosis and solid tumors with a novel technique.
Alentis’s lead therapeutic program, ALE.F02, started clinical studies in Dec 2021 under FDA approval for the Alentis Phase 1 study design. ALE.F02 is currently being developed for the treatment of advanced liver, kidney, and lung fibrosis.

Led by a highly entrepreneurial and experienced management team and a world-class founder, with expertise in fibrosis, rare diseases, and cancer, Alentis is driven to bring life-saving treatments to patients with fibrotic conditions. Alentis’s headquarter is in Basel, Switzerland, with affiliated research and development operations in Strasbourg, France.